These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 5125757)

  • 1. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa.
    Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyridoxine antagonism of levodopa in parkinsonism.
    Leon AS; Spiegel HE; Thomas G; Abrams WB
    JAMA; 1971 Dec; 218(13):1924-7. PubMed ID: 5171069
    [No Abstract]   [Full Text] [Related]  

  • 4. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

  • 5. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
    Weiner WJ; Klawans HL
    J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption and metabolism of levodopa.
    Abrams WB; Coutinho CB; Leon AS; Spiegel HE
    JAMA; 1971 Dec; 218(13):1912-4. PubMed ID: 5171067
    [No Abstract]   [Full Text] [Related]  

  • 8. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 9. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.
    Weiner W; Harrison W; Klawans H
    Life Sci; 1969 Sep; 8(17):971-6. PubMed ID: 5808572
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 11. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting response to levodopa.
    Lakke JP; Korf J; van Praag HM
    Lancet; 1971 Jul; 2(7716):164-5. PubMed ID: 4104491
    [No Abstract]   [Full Text] [Related]  

  • 13. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 14. A study of spinal fluid homovanillic acid (HVA) in patients with diseases of the nervous system.
    Mones RJ; Wilk S; Green J; Jutkowitz R
    Mt Sinai J Med; 1972; 39(5):478-85. PubMed ID: 4538762
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal homovanillic acid and parkinsonism.
    Miachon S; Dalmaz Y; Cottet-Emard JM; Peyrin L
    Biomedicine; 1974 Jul; 21(7):303-8. PubMed ID: 4433665
    [No Abstract]   [Full Text] [Related]  

  • 16. [Determination of homovanillic acid in the cerebrospinal fluid of Parkinson's disease patients and control group].
    Voto Bernales J; Cruz GA; Davila E
    Rev Neuropsiquiatr; 1973 Mar; 36(1):46-52. PubMed ID: 4793023
    [No Abstract]   [Full Text] [Related]  

  • 17. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
    Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
    N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
    [No Abstract]   [Full Text] [Related]  

  • 18. Cerebrospinal fluid homovanillic acid and iso-homovanillic acid: a gas-liquid chromatographic method.
    Dziedzic SW; Gitlow SE
    J Neurochem; 1974 Mar; 22(3):333-5. PubMed ID: 4829959
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):1-5. PubMed ID: 5531292
    [No Abstract]   [Full Text] [Related]  

  • 20. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.